Localized Prostate Cancer VL

Treatment-Specific Out-of-Pocket Costs for Patients Undergoing Localized Prostate Cancer Journal Club - Christopher Wallis & Zachary Klaassen

Details
In this UroToday Journal Club Christopher Wallis and Zachary Klaassen highlight the Urologic Oncology publication entitled Out-of-pocket costs for commercially insured patients with localized prostate cancer. Financial burdens may contribute to long-term effects on patient's health-related quality of life. However, costs are rarely included in shared decision-making conversations, and most studies...

Differences in Mental Health Outcomes According to the Treatment Received for Men Being Treated with Localized Prostate Cancer Journal Club - Christopher Wallis & Zachary Klaassen

Details
Christopher Wallis and Zachary Klaassen discuss The Journal of Urology publication entitled "Association Between Treatment for Localized Prostate Cancer and Mental Health." This study compares patient-reported mental health outcomes for men undergoing treatment for localized prostate cancer over 5 years using the Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) study. Biographi...

Using MRI to Safely Prevent Unnecessary Protocol-Advised Repeat Biopsy During Active Surveillance Journal Club - Christopher Wallis & Zachary Klaassen

Details
In this UroToday Journal Club, Chris Wallis and Zach Klaassen highlight a European Urology Oncology publication entitled Multivariable Approach Using Magnetic Resonance Imaging to Avoid a Protocol-Based Biopsy in Men on Active Surveillance for Prostate Cancer -- Data from the Multi-International Multicenter Prospective PRIAS Study . In general, the use of MRI prior to initial biopsy is now relativ...

Comparing the Relative Benefits of Radiotherapy Dose Escalation ± Short-Term or Long-Term ADT as Treatment Intensification for Localized Prostate Cancer Journal Club - - Christopher Wallis & Zachary K...

Details
In this UroToday Journal Club, Chris Wallis and Zach Klaassen highlight a European Urology publication entitled High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium . Radiotherapy is a standard-of-care treatment approach for patients with localized prosta...

10-year Results DART 01-05, High-dose Radiotherapy and Risk-adapted Androgen Deprivation in Localized Prostate Cancer Journal Club - Christopher Wallis & Zachary Klaassen

Details
In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen review The Lancet Oncology publication High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05) looking at its 10-year results. Radiotherapy is a standard treatment option in patients with localized prostate cancer. With conventional dosing of radiotherapy, the addition of androgen...

The Molecular Biology of Prostate Cancer - Christopher Barbieri

Details
Christopher Barbieri joins Matthew Cooperberg for a discussion about the molecular biology of localized prostate cancer. Dr. Barbieri explains how the underlying molecular and genomic features that separate prostate cancer subtypes can be studied using DNA sequencing and RNA sequencing. The conversation covers predictive markers including DECIPHER, PAM50, genomic mutations, and oncogenic drivers....

DNA Repair Genes Associated With Localized Prostate Cancer, Journal Club - Christopher Wallis & Zachary Klaassen

Details
Christopher Wallis and Zachary Klaassen discuss a publication entitled, “Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer”. Dr. Wallis discusses DNA damage repair mutations and how they present in men with localized prostate cancer. They also discuss the specific genomic mutations seen most commonly in men with DNA damage repair mutations affecting their prosta...

The Role of Imaging Before and After Diagnosis of Localized Prostate Cancer - Masoom Haider

Details
Masoom Haider, a presenter at the 2022 AdMeTech Global Summit for Prostate Cancer, joins Phillip Koo to discuss the upcoming 6th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer where he'll present on radiomics and machine learning. Dr. Haider provides a high level overview of radiomics and the potential there is within this field. In November 1997, AdMeTech Foundation was est...

Deciding Against Active Surveillance: How Genomic Testing Impacted Treatment Decision-Making Among a Predominantly African American Population - Peter Gann and Adam Murphy

Details
Peter Gann and Adam Murphy join Ashley Ross to discuss how the use of the Genomic Prostate Score (GPS) may intersect with patient health literacy to affect decision-making regarding prostate cancer treatment. The discussion begins with an overview of genomics in prostate cancer, particularly the lack of validation of the Oncotype DX assay on African American men. From there, the conversation then...

How Genomic Testing Impacts NCCN Risk Classification of Black Men with Low and Intermediate Risk Prostate Cancer - Andrew Winer

Details
Andrew Winer and Ashley Ross engage in conversation about critical questions surrounding genomic testing and its impact on active surveillance and NCCN risk classification within the African American population. Dr. Winer points out that prostate cancer transforms into more clinically significant disease, grows faster, and often metastasizes earlier in African American men versus Caucasian men. He...
email news signup